Big Pharma Shake-Up: This Chinese Biotech's Drug Just Crushed Global Rivals

Very Bullish

What Happened

RemeGen's Telitacicept shows best-in-class 48-week minimal symptom expression (MSE) data in generalized myasthenia gravis (gMG), with 42% of patients achieving MSE at any time point, surpassing Argenx's efgartigimod (40% at 4 weeks, 45.5% at 10 weeks) and other C5/FcRn/CD19 competitors (20-30%).

Bottom Line

Telitacicept's strong MSE data positions RemeGen as a serious contender in the gMG market, with catalysts ahead in 2027.

Free preview — more China A-share & HK research · About Us · Legal & Privacy